{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:52:34Z","timestamp":1788555154740,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cca.2023.117678","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T17:57:58Z","timestamp":1701367078000},"page":"117678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Development and validation of equilibrium dialysis UHPLC-MS\/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIV"],"prefix":"10.1016","volume":"552","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-074X","authenticated-orcid":false,"given":"Ra\u00fal","family":"Rigo-Bonnin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Garc\u00eda-Tejada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virg\u00ednia","family":"Mas-Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkaitz","family":"Imaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Manuel Tiraboschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Sc\u00e9vola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Niub\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Navarro-Alcaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2023.117678_b0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/FTD.0000000000000684","article-title":"IATDMCT Anti-Infective Committee, impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of people living with HIV: a narrative review","volume":"42","author":"Cattaneo","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2023.117678_b0010","unstructured":"Department of Health and Human Services, Working Group of Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the use of antiretroviral agents in adults and adolescents with HIV, 2023, https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv (accessed 10 Aug 2023)."},{"key":"10.1016\/j.cca.2023.117678_b0015","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.drudis.2014.11.010","article-title":"Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines","volume":"20","author":"Illamola","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cca.2023.117678_b0020","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/jps.24506","article-title":"Plasma protein binding of challenging compounds","volume":"104","author":"Riccardi","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.cca.2023.117678_b0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00216-010-3737-1","article-title":"Drug-protein binding: a critical review of analytical tools","volume":"398","author":"Vuignier","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.cca.2023.117678_b0030","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/FTD.0b013e3181817318","article-title":"Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction","volume":"30","author":"Fayet","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2023.117678_b0035","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1016\/j.xphs.2017.09.005","article-title":"Industry perspective on contemporary protein-binding methodologies: considerations for regulatory drug-drug interaction and related guidelines on highly bound drugs","volume":"106","author":"Di","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.cca.2023.117678_b0040","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.cca.2023.117678_b0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jpba.2013.08.002","article-title":"Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC\u2013MS\/MS technology","volume":"86","author":"Djerada","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cca.2023.117678_b0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpba.2017.02.002","article-title":"UPLC\u2013MS\/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma","volume":"138","author":"Simiele","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cca.2023.117678_b0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cca.2017.12.034","article-title":"Determination of dolutegravir's unbound fraction in human plasma using validated equilibrium dialysis and LC-MS\/MS methods","volume":"479","author":"Metsu","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2023.117678_b0060","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02492-18","article-title":"In vitro evaluation of the drug interaction potential of doravirine","volume":"63","author":"Bleasby","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cca.2023.117678_b0065","article-title":"UPLC\u2013MS\/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma","volume":"181","author":"Gougeta","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cca.2023.117678_b0070","doi-asserted-by":"crossref","DOI":"10.1002\/jms.4506","article-title":"Development and validation of a multiplex UHPLC-MS\/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV","volume":"55","author":"Courlet","year":"2020","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.cca.2023.117678_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113250","article-title":"Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS\/MS","volume":"185","author":"Rigo-Bonnin","year":"2020","journal-title":"J Pharm. Biomed. Anal."},{"key":"10.1016\/j.cca.2023.117678_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113923","article-title":"Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS\/MS","volume":"196","author":"Zheng","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cca.2023.117678_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115010","article-title":"Validation of an LC-MS\/MS assay for the simultaneous determination of bictegravir, doravirine, and raltegravir in human plasma","volume":"220","author":"Schauer","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cca.2023.117678_b0090","unstructured":"European Medicines Agency, ICH guideline M10 on bioanalytical method validation and study sample analysis, Step 5 [Online] European Medicines Agency, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf (Accessed 10 Aug 2023)."},{"key":"10.1016\/j.cca.2023.117678_b0095","unstructured":"Clinical and Laboratory Standard Institute, Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline (CLSI C62-A), CLSI, Wayne, PA, 2022."},{"key":"10.1016\/j.cca.2023.117678_b0100","unstructured":"Clinical and Laboratory Standard Institute, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline (EP06-A2), CLSI, Wayne, PA, 2020."},{"key":"10.1016\/j.cca.2023.117678_b0105","doi-asserted-by":"crossref","unstructured":"D. Podzamczer, A. Imaz, A. Lopez-Lirola, H. Knobel, M. Masi\u00e1, C. Fanciulli, et al., 2023, Switching to bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) plus darunavir\/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens, J. Antimicrob. Chemother. Sep 19, dkad285, doi: 10.1093\/jac\/dkad285.","DOI":"10.1093\/jac\/dkad285"},{"key":"10.1016\/j.cca.2023.117678_b0110","article-title":"Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide versus dolutegravir\/abacavir\/lamivudine in antiretroviral-naive adults (SYMTRI): a multicenter randomized open-label study (PReEC\/RIS-57)","volume":"9","author":"Podzamczer","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.cca.2023.117678_b0115","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/cid\/ciab835","article-title":"Total and unbound doravirine concentrations and viral suppression in CSF","volume":"74","author":"Tiraboschi","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cca.2023.117678_b0120","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(21)00100-4","article-title":"Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial","volume":"8","author":"Rojas","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cca.2023.117678_b0125","first-page":"137","article-title":"Properties and units in the clinical laboratory sciences, Part XXIII, The NPU terminology, principles, and implementation: a user\u2019s guide (IUPAC Technical Report)","volume":"84","author":"Magdal","year":"2012","journal-title":"Pure Appl. Chem."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123004801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123004801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:14:32Z","timestamp":1757862872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898123004801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":25,"alternative-id":["S0009898123004801"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2023.117678","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of equilibrium dialysis UHPLC-MS\/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIV","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2023.117678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117678"}}